Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

  • A. Elkrief Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Cedars Cancer Centre, McGill University Health Centre, Centre de recherche du Centre hospitalier de l’Universtité de Montréal
  • P. Joubert Institut universitaire de cardiologie et de pneumologie de Québec
  • M. Florescu Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
  • M. Tehfe Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
  • N. Blais Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
  • B. Routy Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
Keywords: Lung Cancer, Immunotherapy, Targeted therapy, Chemotherapy Biomarker

Abstract

Lung cancer is the most commonly diagnosed cancer in Canada and remains associated with high mortality. Never- theless, recent advances in the fields of immuno-oncology and precision medicine have led to significant improve- ments in clinical outcome in metastatic non-small-cell lung cancer (nsclc). Those improvements were facilitated by a greater understanding of the biologic classification of nsclc, which catalyzed discoveries of novel therapies. Here, we present a comprehensive review of the recent avalanche of practice-changing trials in metastatic nsclc, and we offer an approach to the management of this disease from a Canadian perspective. We begin with an overview of the pathologic and molecular characterization of metastatic nsclc. Next, we review the indications for currently approved immune checkpoint inhibitors, and we provide an approach to the management of disease with a driver mutation. Finally, we address future avenues in both diagnostics and therapeutics for patients with advanced and metastatic nsclc.


Author Biographies

M. Florescu, Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal

Division of Hematology-Oncology

M. Tehfe, Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
Division of Hematology-Oncology
N. Blais, Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
Division of Hematology-Oncology
B. Routy, Centre de recherche du Centre hospitalier de l’Universtité de Montréal, Centre hospitalier de l’Université de Montréal
Division of Hematology-Oncology
Published
2020-03-06
How to Cite
Elkrief, A., Joubert, P., Florescu, M., Tehfe, M., Blais, N., & Routy, B. (2020). Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020. Current Oncology, 27(1). https://doi.org/10.3747/co.27.5953
Section
Review Article